WINSTON-SALEM, N.C.--(BUSINESS WIRE)--Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing a new class of drugs known as NNR Therapeutics(TM), today announced that it will conduct a conference call and audio webcast at 5:00 p.m. EDT on Tuesday, August 7, 2007 following the after-market release of its unaudited financial results for the second quarter ended June 30, 2007. J. Donald deBethizy, Ph.D., President and Chief Executive Officer, and Alan A. Musso, Vice President and Chief Financial Officer, will host the call, during which they will discuss Targacept’s financial results and provide an update on the company’s product development programs and business activities.
